x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0231380
| Product Information | |
|---|---|
| CAS No. | 221244-14-0 |
| Synonyms | Mutant Kinases Inhibitor II, PP1 ANALOG II |
| Chemical Name | 1-(1,1-dimethylethyl)-3-(1-naphthalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
| Formula | C20H21N5 |
| Molecular Weight | 331.41 |
| PubChem CID | 5154691 |
| SMILES | CC(C)(C)N1C2=C(C(=N1)CC3=CC=CC4=CC=CC=C43)C(=NC=N2)N |
| Target | Tyrosine kinase |
| Product Description | mutant tyrosine kinase inhibitor |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 98% |
| Shipping | Shipped on dry ice. |
| Storage | Store at -20 °C. This product is air and light sensitive and impurities can occur as a result of air oxidation or due to metabolism by microbes. |
| Solubility Overview | Soluble in DMSO to 75 mM |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
